Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma-Reference-Cited by-同舟云学术

Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma

Published:2023-12 Issue:12 Volume:4 Page:101302
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Duan Jianchun,Zhang Yun,Chen Ran,Liang Liang,Huo Yi,Lu Shun,Zhao Jun,Hu Chunhong,Sun Yuping,Yang Kunyu,Chen Mingwei,Yu Yan,Ying Jianming,Huang Ruiqi,Ma Xiaopeng,Leaw Shiangjiin,Bai Fan,Shen Zhirong,Cai Shangli,Gao Daming,Wang Jie,Wang Zhijie^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference54 articles.

1. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial;Jotte;J. Thorac. Oncol.,2020

2. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer;Paz-Ares;N. Engl. J. Med.,2018

3. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial;Wang;JAMA Oncol.,2021

4. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12);Zhou;J. Thorac. Oncol.,2021

5. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral Blood Biomarkers Predicting the Efficacy of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Retrospective Study;2024-07-02

2. Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure;ESMO Open;2024-07